Svetlana Blitshteyn

Dr. Svetlana Blitshteyn

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Immunologic Research
Verified
Journal Article
Open access
PDF file
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn
SWSera Whitelaw
Sera Whitelaw
Objective To describe clinical features, diagnostic findings, treatments, and outcomes in patients with new-onset postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders following SARS-CoV-2 infection (COVID-19). Methods We retrospectively reviewed medical records for patients who presented with persistent neurologic and cardiovascular complaints between April and December 2020 following COVID-19 infection. Results Twenty patients (70% female) were included in this study.Fifteen had POTS, 3 had neurocardiogenic syncope, and 2 had orthostatic hypotension. Six patients had abnormalities on cardiac or pulmonary testing, and 4 had elevated autoimmune or inflammatory markers. All patients were treated with non-pharmacologic therapies, and most required pharmacologic therapies. Six to 8 months after COVID-19, 17 (85%) patients had residual autonomic symptoms, with 12 (60%) unable to return to work. Conclusions POTS can follow COVID-19 in previously healthy patients. Appropriate diagnostic investigations and therapies are necessary to identify and treat autonomic dysfunction after COVID-19.

1 June 2015 in Lupus
Verified
Journal Article
Closed access
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn
In recent years, there have been a number of studies suggesting that POTS may have an autoimmune etiology. This study examined whether the prevalence of antinuclear antibodies (ANA), other markers of autoimmunity and co-morbid autoimmune disorders is higher in patients with POTS than in the general population. Medical records of 100 consecutive patients with POTS evaluated at our clinic were reviewed. In this cohort (90% females, mean age 32, range 13–54 years), 25% had positive ANA, 7% had at least one positive aPL antibody and 31% had markers of autoimmunity. When compared to the general population, patients with POTS had a higher prevalence of ANA (25% vs. 16%, OR 1.8, CI 1.1–2.8, p < 0.05), aPL antibody (7% vs. 1%, OR 7.5, CI 3.4–16.1, p < 0.001) and co-morbid autoimmune disorders (20% vs. highest estimated 9.4%, OR 2.4, CI 1.5–3.9, p < 0.001). The most prevalent autoimmune disorder was Hashimoto’s thyroiditis (11% vs. up to 2%, OR 6.1, CI 3.2–11.3, p < 0.001), followed by RA (4% vs. up to 1%, OR 4.1, CI 1.5–11.2, p < 0.01) and SLE (2% vs. up to 0.12%, OR 17, CI 4.1–69.7, p < 0.001). The prevalence of CVID was very high (2% vs. 0.004%, OR 510.2, CI 92.4–2817.8, p < 0.001), while celiac disease showed a nonsignificant trend toward increased prevalence. Patients with POTS have a higher prevalence of autoimmune markers and co-morbid autoimmune disorders than the general population. One in four patients have positive ANA, almost one in three have some type of autoimmune marker, one in five have a co-morbid autoimmune disorder, and one in nine have Hashimoto’s thyroiditis.

28 September 2022 in PM&R
Verified
Journal Article
Closed access
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn
JWJonathan Harris Whiteson
Jonathan Harris Whiteson
BABenjamin Abramoff
Benjamin Abramoff
AAAlba Azola
Alba Azola
MBMatthew N. Bartels
Matthew N. Bartels
David  PutrinoDavid Putrino
David Putrino

16 September 2013 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn

25 August 2016 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn
JBJill Brook
Jill Brook

7 March 2021 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Svetlana BlitshteynSvetlana Blitshteyn
Svetlana Blitshteyn